Dr. Eberling received her PhD from the University of California at Berkeley and did her post-doctoral training in PET imaging at the Lawrence Berkeley National Laboratory. Prior to joining the Michael J. Fox Foundation (MJFF) in 2009, she did research using PET imaging to study Alzheimer’s disease and Parkinson’s disease and was involved in the development and translation of gene therapy approaches for Parkinson’s disease using AADC PET imaging as a readout for therapeutic response to AAV-AADC gene therapy. She also worked on the preclinical development of AAV-GDNF gene therapy for Parkinson’s disease. At the Michael J. Fox Foundation (MJFF), Dr. Eberling has been involved in a number of different programs over the years. Most notably, Dr. Eberling has overseen the PET imaging program since 2009 and launched the Foundation’s dedicated effort to develop a selective alpha-synuclein PET tracer in 2010. Since that time, MJFF has funded over 30 million dollars toward this effort and in 2016 Dr. Eberling announced a 2 million dollar prize to the first group to develop a selective alpha-synuclein PET tracer. Although the prize has yet to be awarded much progress has been made and MJFF hopes to award the prize in the near future. Dr. Eberling is now the head of the Research Resources Department which includes imaging (PET and MRI), laboratory tools (reagents and antibodies), data, biospecimens, and open access publications. She continues to lead the PET tracer development program with a focus on the development of novel PET tracers for a variety of different pathological and therapeutic targets.

Brandon Ebright is a 5th year PhD candidate at the University of Southern California (Los Angeles, CA, USA) pursuing his degree in Clinical and Experimental Therapeutics under Dr. Stan Louie and Dr. Hussein Yassine from USC Keck School of Medicine. The focus of his graduate research involved understanding Alzheimer’s disease pathophysiology and the mechanism(s) by which neuroinflammation and altered fatty acid metabolism contribute to disease progression, as well as the development of small-molecule therapeutics targeting these processes. Prior to his graduate studies, Brandon obtained his B.S. in Chemistry from Rice University (Houston, TX, USA) in 2019.

I studied at the University of Heidelberg, Germany, and performed my PhD thesis in the lab of Prof. Dr. Dr. Kontad Beyreuther (July 2004). Afterwards, I spent my first postdoc time in the lab of Prof. Dr. Edward Koo at UCSD, San Diego, USA (6 years). Subsequently I was working as a research associate at the University of Kaisersautern in the lab of Prof. Dr. Stefan Kins (Habilitation 2022). I am working since April 2022 in the lab of Prof. Dr. Klaus-Armin Nave at the Max-Planck-Institute for multidisciplinary sciences in Göttingen (Umhabilitation at the University of Göttingen March 2023). During all this time I was working in the Alzheimer´s disease research field, mainly on APP/APLP1/APLP2 processing, trafficking and dimerization and the APP family members as synaptic adhesion molecules.

Simona Eleuteri is a faculty member at Harvard Medical School and her research is focused on preclinical translational studies to identify promising therapeutic approaches to block the degeneration and progression of neurodegenerative disorders, which includes Parkinson's disease (PD), Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). Her current projects combine cell culture, pluripotent-stem (iPS) cells and murine models to elucidate underlying pathological mechanisms associated to neurodegeneration, giving special attention to the aggregation, accumulation, propagation and clearance of amyloid proteins.

Andreja Emeršič, European Specialist in Laboratory Medicine (EUSpLM), is a deputy head of the Laboratory for CSF diagnostics at the Department of Neurology, University Medical Centre Ljubljana. Her research interests are focused on cerebrospinal fluid and other fluid biomarkers of neurodegenerative and demyelinating diseases. She is a PhD student in the Interdisciplinary Doctoral Programme Biomedicine, in the field of Clinical Biochemistry and Laboratory Biomedicine at the University of Ljubljana.

Pierre is trained both in Epidemiology (MPH, PhD) and in pharmacy (PharmD) with 12+ years of experience in the field of Epidemiology in academia, consultancy firms and CROs. Through his various positions at he has demonstrated over the last years strong expertise in the field of epidemiology and RWE but also business acumen to support the growth of RWE capabilities in the companies he worked for (Certara, IQVIA, Aetion, Centogene). Former EMA appointed expert and point of contact for Aetion for EMA funded studies, he is a former Steering Group Member (2014-2016) of the European Network of Centres of Pharmacovigilance and Pharmaco-epidemiology (ENCePP) and the Working Group on transparency (EU-PAS register). Specialized in European PharmacoEpi Drug Safety, Pierre has also a strong track record of successfully designed RWE regulatory grade studies such as global PASS, multi database HEOR programs, or global registries. He has contributed or overseen at different stage a total of 25+ of observational studies over the last ten years for various Marketing Autorisation Holders. Author of numerous publications in intl. peer reviewed journals (including International and American Journal of Epidemiology & Pharmacoepidemiology and Drug Safety), he has also frequently supervised MPH or PharmD.

Lizzie is a third year PhD student based in Professor Sir David Klenerman’s group at the University of Cambridge. She uses single molecule techniques, including super-resolution microscopy and Simoa, to perform detailed measures of protein aggregates. Her project aims to better characterise the diverse range of protein aggregates in the human brain, and to improve understanding of how these change in different brain regions across Alzheimer’s disease (AD). Her work has uncovered details of tau aggregation from human post-mortem brain-derived homogenates, through measuring tau aggregate quantities, sizes, and shapes, as well as phosphorylation status. Alongside her PhD, Lizzie has founded Women in Neuroscience UK, a 30-person volunteer team delivering events, blogs, and social media content, with aims to inspire, connect, and advocate for women and girls interested in neuroscience. WiNUK engages an audience of all genders and career stages, based in the UK and around the world.